BME100 f2015:Group4 1030amL2
BME 100 Fall 2015 | Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help | ||||||
OUR TEAMLAB 2: Means, Standard Deviations, t-test, and ANOVAsDescriptive StatisticsExperiment 1 An ANOVA was completed for the human data since multiple levels of dosages were present. A post-hoc was used due to a significant result on the ANOVA.
A t-test was completed for the rat data because only two levels of LPS were presented in this sample.
ResultsExperiment 1 Experiment 2
AnalysisExperiment 1
We are more than 99% confident that there is a significant difference in the Inflammotin protein levels, in pg/mL, between the four groups of humans receiving 0 mg, 5 mg, 10, mg, and 15 mg of LPS. We are more than 99% confident that there is a significant difference in the Inflammotin protein levels, in pg/mL, between 0 v. 5 mg, 5 v. 10 mg, 10 v. 15 mg, 0 v. 10 mg, 0 v. 15 mg, and 5 v. 15 mg of LPS. Therefore, there is sufficient evidence to conclude that there is a significant difference in the Inflammotin protein level in result of the difference in LPS dosage amounts.
Summary/DiscussionGiven the differing results between the human and rat studies, it may be concluded that Inflammoton has a significant effect on humans, and a lesser effect on rats. Seeing as there is little difference in the Inflammotin protein levels between the two dosages in rats, given a high P-value, there is not sufficient evidence that LPS dosages dramatically effect rat protein levels. In addition, given the low P-value, there is sufficient evidence that differing LPS dosages causes a differing amount of Inflammotin protein level growth in humans. |